651 related articles for article (PubMed ID: 24727335)
21. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1859-66. PubMed ID: 22863841
[TBL] [Abstract][Full Text] [Related]
22. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
[TBL] [Abstract][Full Text] [Related]
23. Effect of ABO blood group incompatibility on the outcome of single-unit cord blood transplantation after myeloablative conditioning.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Ebihara Y; Mochizuki S; Yuji K; Ohno N; Kawamata T; Jo N; Yokoyama K; Uchimaru K; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2014 Apr; 20(4):577-81. PubMed ID: 24368297
[TBL] [Abstract][Full Text] [Related]
24. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
25. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia.
Peffault de Latour R; Brunstein CG; Porcher R; Chevallier P; Robin M; Warlick E; Xhaard A; Ustun C; Larghero J; Dhedin N; Mohty M; Socié G; Weisdorf D
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1355-60. PubMed ID: 23791622
[TBL] [Abstract][Full Text] [Related]
26. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
27. The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study.
Ge J; Yang T; Zhang L; Zhang X; Zhu X; Tang B; Wan X; Tong J; Song K; Yao W; Sun G; Sun Z; Liu H
BMC Infect Dis; 2018 Dec; 18(1):654. PubMed ID: 30545330
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience.
Strullu M; Rialland F; Cahu X; Brissot E; Corradini N; Thomas C; Blin N; Rialland X; Méchinaud F; Mohty M
Eur J Haematol; 2012 Jun; 88(6):504-9. PubMed ID: 22372430
[TBL] [Abstract][Full Text] [Related]
29. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
30. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
Gonçalves MV; Yamamoto M; Kimura EY; Colturato VA; de Souza MP; Mauad M; Ikoma MV; Novis Y; Rocha V; Ginani VC; Wanderley de Oliveira Felix OM; Seber A; Kerbauy FR; Hamerschlak N; Orfao A; Rodrigues CA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1223-9. PubMed ID: 25792371
[TBL] [Abstract][Full Text] [Related]
31. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
32. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of unrelated donor umbilical cord blood transplantation for 30 adults with hematological malignancies.
Kobayashi K; Maeda Y; Hara Y; Nishie-Kataoka M; Nishimori H; Sugiyama H; Namba N; Kubonishi S; Niiya M; Shinagawa K; Ikeda K; Tanimoto M
Anticancer Res; 2009 May; 29(5):1763-70. PubMed ID: 19443401
[TBL] [Abstract][Full Text] [Related]
34. T cell-depleted related HLA-mismatched peripheral blood stem cell transplantation as salvage therapy for graft failure after single unit unrelated donor umbilical cord blood transplantation.
Moscardó F; Romero S; Sanz J; Sanz MA; Montesinos P; Lorenzo I; Solves P; Carpio N; Sanz GF
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1060-3. PubMed ID: 24685578
[TBL] [Abstract][Full Text] [Related]
35. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
[TBL] [Abstract][Full Text] [Related]
36. Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.
Liu HL; Sun ZM; Geng LQ; Wang XB; Ding KY; Tong J; Tang BL; Zhou CY; Yao W; Zheng CC; Song KD; Zhu XY; Wei W; Wang Y
Bone Marrow Transplant; 2014 Aug; 49(8):1063-9. PubMed ID: 24842525
[TBL] [Abstract][Full Text] [Related]
37. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
Brunner AM; Kim HT; Coughlin E; Alyea EP; Armand P; Ballen KK; Cutler C; Dey BR; Glotzbecker B; Koreth J; McAfee SL; Spitzer TR; Soiffer RJ; Antin JH; Ho VT; Chen YB
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1374-80. PubMed ID: 23791626
[TBL] [Abstract][Full Text] [Related]
38. [Haploidentical donor peripheral blood stem cell transplantation using third-party cord blood compared with matched unrelated donor transplantation for patients with hematologic malignancies].
Ma X; Chen Y; Liu Y; Cheng TT; Chen X; Zeng C; Hua J; Wang SY; Xu YJ
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):141-147. PubMed ID: 38604790
[No Abstract] [Full Text] [Related]
39. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
[TBL] [Abstract][Full Text] [Related]
40. Cord blood transplantation from unrelated donors for children with acute lymphoblastic leukemia in Japan: the impact of methotrexate on clinical outcomes.
Kato K; Yoshimi A; Ito E; Oki K; Hara J; Nagatoshi Y; Kikuchi A; Kobayashi R; Nagamura-Inoue T; Kai S; Azuma H; Takanashi M; Isoyama K; Kato S;
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1814-21. PubMed ID: 21664471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
